vs
ALTISOURCE PORTFOLIO SOLUTIONS S.A.（ASPS）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
ALTISOURCE PORTFOLIO SOLUTIONS S.A.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.3倍（$42.3M vs $33.4M），ALTISOURCE PORTFOLIO SOLUTIONS S.A.同比增速更快（3.2% vs -23.8%），ALTISOURCE PORTFOLIO SOLUTIONS S.A.自由现金流更多（$-525.0K vs $-47.7M），过去两年ALTISOURCE PORTFOLIO SOLUTIONS S.A.的营收复合增速更高（3.6% vs -6.2%）
Altisource Portfolio Solutions S.A.是面向抵押贷款、房地产及消费金融领域的全球服务商，为贷款机构、服务商、投资者等市场参与者提供技术、数据与运营解决方案，优化资产管理、房产交易等业务流程，提升客户运营效率。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
ASPS vs DNA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $42.3M | $33.4M |
| 净利润 | $-7.1M | — |
| 毛利率 | 26.5% | — |
| 营业利润率 | -15.5% | -211.9% |
| 净利率 | -16.8% | — |
| 营收同比 | 3.2% | -23.8% |
| 净利润同比 | 18.2% | — |
| 每股收益（稀释后） | $-1.02 | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $42.3M | $33.4M | ||
| Q3 25 | $41.9M | $38.8M | ||
| Q2 25 | $43.3M | $49.6M | ||
| Q1 25 | $43.4M | $48.3M | ||
| Q4 24 | $41.0M | $43.8M | ||
| Q3 24 | $40.5M | $89.0M | ||
| Q2 24 | $39.1M | $56.2M | ||
| Q1 24 | $39.5M | $37.9M |
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $-2.3M | $-80.8M | ||
| Q2 25 | $16.7M | $-60.3M | ||
| Q1 25 | $-5.3M | $-91.0M | ||
| Q4 24 | $-8.7M | — | ||
| Q3 24 | $-9.3M | $-56.4M | ||
| Q2 24 | $-8.3M | $-217.2M | ||
| Q1 24 | $-9.2M | $-165.9M |
| Q4 25 | 26.5% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 30.1% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 30.3% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 32.5% | — | ||
| Q1 24 | 31.2% | — |
| Q4 25 | -15.5% | -211.9% | ||
| Q3 25 | 1.2% | -231.8% | ||
| Q2 25 | 7.5% | -132.1% | ||
| Q1 25 | 7.5% | -184.1% | ||
| Q4 24 | 1.4% | -236.3% | ||
| Q3 24 | 2.7% | -62.0% | ||
| Q2 24 | 5.3% | -396.7% | ||
| Q1 24 | -1.4% | -469.1% |
| Q4 25 | -16.8% | — | ||
| Q3 25 | -5.5% | -207.9% | ||
| Q2 25 | 38.5% | -121.6% | ||
| Q1 25 | -12.1% | -188.2% | ||
| Q4 24 | -21.3% | — | ||
| Q3 24 | -23.0% | -63.3% | ||
| Q2 24 | -21.1% | -386.4% | ||
| Q1 24 | -23.2% | -437.3% |
| Q4 25 | $-1.02 | $-1.41 | ||
| Q3 25 | $-0.22 | $-1.45 | ||
| Q2 25 | $1.48 | $-1.10 | ||
| Q1 25 | $-0.09 | $-1.68 | ||
| Q4 24 | $-4.72 | $-1.91 | ||
| Q3 24 | $-2.61 | $-1.08 | ||
| Q2 24 | $-2.33 | $-4.23 | ||
| Q1 24 | $-0.33 | $-3.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.6M | $422.6M |
| 总债务越低越好 | $191.1M | — |
| 股东权益账面价值 | $-110.2M | $508.6M |
| 总资产 | $139.8M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $26.6M | $422.6M | ||
| Q3 25 | $28.6M | $495.5M | ||
| Q2 25 | $30.0M | $559.4M | ||
| Q1 25 | $30.8M | $325.3M | ||
| Q4 24 | $29.8M | $561.6M | ||
| Q3 24 | $28.3M | $616.2M | ||
| Q2 24 | $29.7M | $730.4M | ||
| Q1 24 | $29.6M | $840.4M |
| Q4 25 | $191.1M | — | ||
| Q3 25 | $192.5M | — | ||
| Q2 25 | $193.9M | — | ||
| Q1 25 | $195.0M | — | ||
| Q4 24 | $230.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-110.2M | $508.6M | ||
| Q3 25 | $-104.2M | $559.8M | ||
| Q2 25 | $-102.7M | $613.0M | ||
| Q1 25 | $-119.8M | $647.4M | ||
| Q4 24 | $-157.4M | $716.1M | ||
| Q3 24 | $-149.4M | $797.9M | ||
| Q2 24 | $-140.8M | $833.1M | ||
| Q1 24 | $-133.3M | $987.3M |
| Q4 25 | $139.8M | $1.1B | ||
| Q3 25 | $139.9M | $1.2B | ||
| Q2 25 | $142.9M | $1.2B | ||
| Q1 25 | $145.7M | $1.3B | ||
| Q4 24 | $143.6M | $1.4B | ||
| Q3 24 | $144.5M | $1.5B | ||
| Q2 24 | $146.6M | $1.6B | ||
| Q1 24 | $148.9M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-505.0K | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | $-525.0K | $-47.7M |
| 自由现金流率自由现金流/营收 | -1.2% | -142.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-5.1M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-505.0K | $-47.7M | ||
| Q3 25 | $718.0K | $-31.6M | ||
| Q2 25 | $-306.0K | $-40.3M | ||
| Q1 25 | $-5.0M | $-51.5M | ||
| Q4 24 | $-1.4M | $-42.4M | ||
| Q3 24 | $-1.6M | $-103.5M | ||
| Q2 24 | $180.0K | $-84.4M | ||
| Q1 24 | $-2.2M | $-89.3M |
| Q4 25 | $-525.0K | $-47.7M | ||
| Q3 25 | $697.0K | — | ||
| Q2 25 | $-309.0K | $-40.3M | ||
| Q1 25 | $-5.0M | $-59.1M | ||
| Q4 24 | $-1.4M | $-56.1M | ||
| Q3 24 | — | $-118.6M | ||
| Q2 24 | — | $-111.4M | ||
| Q1 24 | — | $-96.0M |
| Q4 25 | -1.2% | -142.8% | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | -0.7% | -81.2% | ||
| Q1 25 | -11.5% | -122.4% | ||
| Q4 24 | -3.4% | -128.0% | ||
| Q3 24 | — | -133.2% | ||
| Q2 24 | — | -198.2% | ||
| Q1 24 | — | -252.9% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.1% | 15.8% | ||
| Q4 24 | 0.0% | 31.3% | ||
| Q3 24 | 0.0% | 16.9% | ||
| Q2 24 | 0.0% | 48.1% | ||
| Q1 24 | 0.0% | 17.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPS
| Services | $39.9M | 94% |
| Revenue Relatedto Technology Platformsand Professional Services | $2.4M | 6% |
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
